M&AJapan’s Asahi Kasei buys antiviral specialist Aicuris in €780 million dealTakeover in Wuppertal: Aicuris Anti-Infective Cures AG, which specializes in active ingredients for infectious diseases, is being acquired by Japanese pharmaceutical company Asahi Kasei for almost €800 … more ➔
Rare diseaseargenx expands VYVGART into ocular MG as profitability signals franchise maturityargenx delivered two significant updates on the same day: positive Phase 3 results in ocular myasthenia gravis (oMG) and its first full year of operating profitability. Together, the announcements show … more ➔
anti-obesityNovo Nordisk partners with MIT spinout Vivtex in deal worth up to $2.1bn to advance oral biologics for obesityDenmark’s Novo Nordisk has signed a collaboration with Boston-based Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated metabolic diseases. Vivtex … more ➔
AcquisitionGSK buys 35Pharma for $950m, targeting next-generation pulmonary hypertension therapy and the TGF-β superfamilyGSK will pay $950m for Montreal-based 35Pharma to secure HS235, an investigational activin signalling inhibitor that has completed Phase I trials in healthy volunteers and is set to begin studies in … more ➔
BeiersdorfSkin careSkin in the AI game: Beiersdorf Ventures invests in AI biology platform TurbineAs a co-investor in the USD 25 million Series B round, Beiersdorf AG is signalling that artificial intelligence is becoming strategically important for skin research. The Hamburg-based group is participating … more ➔
BrainomixAIBrainomix extends Series C to £18.8m as Oxford AI imaging spinout pushes into the USOxford-based Brainomix has added £4.8 million (approximately $6.5m/€5.5m) to its Series C financing, bringing the total round to £18.8 million ($25.4m/€21.5m) and providing fresh capital to accelerate … more ➔
BioNTech SECancer vaccinationEarly BioNTech mRNA breast cancer trial delivers surprise in longtime disease controlA study recently published in Nature on the use of mRNA “vaccines” targeting cancer neoantigens in triple-negative breast cancer (TNBC) has generated considerable attention in scientific circles. … more ➔
CollaborationAngelini partners with Quiver on AI-driven discovery in genetic epilepsiesItaly’s Angelini Pharma has signed a multi-year research collaboration and licensing agreement with Massachusetts-based Quiver Bioscience to discover new treatments for genetic epilepsies, including … more ➔
Flu vaccinesEurope accelerates next-generation flu vaccines with €225m innovation procurement pushA group of vaccine developers, biotech firms and public health institutes, including Bavarian Nordic and Sanofi, has secured framework contracts under a €225 million EU initiative to accelerate the … more ➔
Unsplash+Clinical DataMoonLake’s sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s BimzelxMost inflammatory arthritis patients on MoonLake Immunotherapeutics’ sonelokimab met the response criteria, furthering the Swiss biotech’s attempt to challenge UCB for a blockbuster market. more ➔
Beiersdorf
Brainomix
BioNTech SE
Unsplash+